Industry-related

AbCellera is growing!

On the evening of Tuesday October 16^th 2018, AbCellera opened its doors to the local biotech, research, and business community to celebrate the official opening of its new space. AbCellera moved from its incubation space at UBC to a 21,000 square foot building with new offices and custom-built laboratories. Carl Hansen, CEO of AbCellera, thanked UBC and colleagues in the Vancouver biotech community for playing a crucial role in helping the company get started.

To read the full article on AbCellera’s website, please click here.

Industry-related

A transition to translation: Dr. Carl Hansen

MSL research group spins-out an industry-leading biotechnology company

AbCellera awarded contract to develop a rapid response platform against pandemic viral threats

AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with congenital degenerative diseases

AbCellera named one of Canada’s top growing companies

AbCellera wins 2019 Technology Impact Award for Company of the Year – Scale Success

Tackling the world’s deadliest diseases one Ab at a time: an interview with Dr. Carl Hansen